Current status of carbazole hybrids as anticancer agents

Eur J Med Chem. 2022 Feb 5:229:113999. doi: 10.1016/j.ejmech.2021.113999. Epub 2021 Nov 20.

Abstract

The drug resistance and low specificity of current available chemotherapeutics to cancer cells are the main reasons responsible for the failure of cancer chemotherapy and remain dramatic challenges for cancer therapy, creating an urgent need to develop novel anticancer agents. Carbazole nucleus, widely distributed in nature, is a predominant feature of a vast array of biologically active compounds. Carbazole derivatives exhibited potential antiproliferative activity against different cancer cell lines by diverse mechanisms, inclusive of arrest cell cycle and induce apoptosis, and several anticancer agents are carbazole-based compounds. Thus, carbazole derivatives represent a fertile source for discovery of novel anticancer therapeutic agents. Over the past several years, a variety of carbazole hybrids have been developed as potential anticancer agents. The present review focuses on the recent progress, from 2016 until now, in knowledge on anticancer properties, structure-activity relationships and mechanisms of action of carbazole hybrids to provide a basis for development of relevant therapeutic agents.

Keywords: Cancer; Carbazole; Drug resistance; Hybrid molecules; Mechanisms of action; Structure-activity relationships.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology
  • Carbazoles / chemistry*
  • Carbazoles / pharmacology
  • Cell Cycle Checkpoints / drug effects
  • Cell Proliferation / drug effects
  • Coumarins / chemistry
  • Humans
  • Indoles / chemistry
  • Pyrazoles / chemistry
  • Pyrimidines / chemistry
  • Structure-Activity Relationship

Substances

  • Antineoplastic Agents
  • Carbazoles
  • Coumarins
  • Indoles
  • Pyrazoles
  • Pyrimidines